Glenmark Pharma.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
India considers nicotine pouches a new public health risk
Adani airport faces scrutiny from India drugs, customs officials
Group disputes conclusion that pouch sales are 'breach of law'
Adani group says drug, cosmetics law should not apply to such sales
Adani has mounted court challenge against scrutiny
Updates July 7 story to add July 8 Adani comment in paragraphs 8-9, 15, bullet
By Aditya Kalra
NEW DELHI, July 7 (Reuters) - An Indian investigation found that Mumbai international airport's duty-free shops run by billionaire Gautam Adani's business group breached the law by selling nicotine pouches, which the government considers a public health hazard, according to documents from the investigation.
Adani denies wrongdoing and is asking judges to declare that a law covering drugs and cosmetics does not apply to duty-free shops and nicotine pouches, according to court papers reviewed by Reuters. Lawyers say the case could set a precedent on how India regulates sales at such outlets and a government win could block sales of one of the world's fastest-growing nicotine products in India's airports.
India banned e-cigarettes and approved certain nicotine replacements like patches and chewing gums following a registration process under the Drugs and Cosmetics Act. Nicotine pouches remain illegal and unapproved.
INDIA DEFINES NICOTINE POUCHES AS 'A DRUG'
The Indian government says tobacco kills 1.35 million people each year in India. A government study in June called nicotine pouches "a new and largely unregulated public health concern", with widespread illegal sales and consumption among people aged 18 to 40.
After receiving complaints from anti-nicotine group Mothers Against Vaping, India's drug department inspected duty-free shops at Mumbai's international airport in March and found imported nicotine pouches were being sold in the departure zone without the necessary approvals, government documents show.
"Nicotine pouches also fall under the definition of a drug ... a valid registration certificate and import license are mandatory," an assistant drugs controller wrote in an April 2 letter to the airport's customs authority, attaching an "investigation report".
The government asked Mumbai Travel Retail, a joint venture led by Adani with Dubai's Flemingo, to discontinue sales of nicotine pouches and seek approvals, government letters show.
Adani did not respond to Reuters queries ahead of the story’s publication. Late on Wednesday, its spokesperson said in an email that the characterisation of "the matter as a 'breach of law' is premature and legally unsustainable", adding that Mumbai Travel Retail has “challenged the regulatory interpretation through judicial review.”
“International passengers arriving in India may lawfully carry nicotine pouches purchased overseas for personal consumption," the Adani statement said. "Yet the sale of identical products through an international duty-free channel has been treated differently. This apparent inconsistency forms part of the legal challenge."
Flemingo and the Indian health and customs authority did not respond to requests for comment.
Selling a drug without a license could draw a prison term of at least three years and a fine of at least 100,000 rupees ($1,000) or three times the value of the drugs confiscated, whichever is higher.
Reuters is first to report the details of the investigation into Adani sales and its court challenge in Mumbai.
Adani's firm has told authorities the shops in the international departure area conduct business "beyond the customs frontiers of India" and are outside the reach of domestic regulations, its non-public High Court filing shows.
CAN GUNS BE SOLD AT AIRPORT?
Asked about the Adani group's point, Murali Neelakantan, former general counsel at Indian drugmakers Cipla and Glenmark Pharmaceuticals, told Reuters: "If a murder occurs in the store, will Indian police have no powers to arrest? They will have ... Can (the store) sell guns or ammunition? No."
The Adani statement responded: "Firearms are prohibited from duty free retail world over because they pose an inherent threat to aviation safety. Drawing a parallel between firearms and regulated nicotine products has no bearing on the legal issues before the Court."
On June 24, judges in Mumbai's High Court said "no coercive action" should be taken on the existing stock of pouches at Mumbai's duty-free shops, scheduling the case for a July 14 hearing.
Adani runs eight airports in India and is targeting an $11 billion expansion that includes a bet on duty-free offerings. At Mumbai's international airport, it runs more than 30 duty-free shops.
In court, Adani said nicotine pouches "are not a drug" and are a "recent innovation" that was not anticipated by existing tobacco control laws, documents show.
Since August, Adani's firm imported Philip Morris' PM.N Zyn nicotine pouches in various flavours worth more than $29,000, and the White Fox brand from Swedish Smokeless Solutions worth $7,700, customs records showed. Those companies did not respond to Reuters queries.
Philip Morris says Zyn's U.S. sales doubled last year from 2023. The June Indian government study said both Zyn and White Fox were being sold by Indian vendors illegally.
Separately, Flemingo Dutyfree has told the High Court it operates shops at international seaports — including in Mumbai — and fears similar actions as it was "in the process of stocking" nicotine pouches, documents show.
Seeking licenses for nicotine pouches will compel suppliers to withdraw them from the market, making "the duty free industry in India unattractive to passengers," it said.
(Reporting by Aditya Kalra; Additional reporting by Arpan Chaturvedi; Editing by Thomas Derpinghaus and William Mallard)
((Email: [email protected]; X: @adityakalra;))
India considers nicotine pouches a new public health risk
Adani airport faces scrutiny from India drugs, customs officials
Group disputes conclusion that pouch sales are 'breach of law'
Adani group says drug, cosmetics law should not apply to such sales
Adani has mounted court challenge against scrutiny
Updates July 7 story to add July 8 Adani comment in paragraphs 8-9, 15, bullet
By Aditya Kalra
NEW DELHI, July 7 (Reuters) - An Indian investigation found that Mumbai international airport's duty-free shops run by billionaire Gautam Adani's business group breached the law by selling nicotine pouches, which the government considers a public health hazard, according to documents from the investigation.
Adani denies wrongdoing and is asking judges to declare that a law covering drugs and cosmetics does not apply to duty-free shops and nicotine pouches, according to court papers reviewed by Reuters. Lawyers say the case could set a precedent on how India regulates sales at such outlets and a government win could block sales of one of the world's fastest-growing nicotine products in India's airports.
India banned e-cigarettes and approved certain nicotine replacements like patches and chewing gums following a registration process under the Drugs and Cosmetics Act. Nicotine pouches remain illegal and unapproved.
INDIA DEFINES NICOTINE POUCHES AS 'A DRUG'
The Indian government says tobacco kills 1.35 million people each year in India. A government study in June called nicotine pouches "a new and largely unregulated public health concern", with widespread illegal sales and consumption among people aged 18 to 40.
After receiving complaints from anti-nicotine group Mothers Against Vaping, India's drug department inspected duty-free shops at Mumbai's international airport in March and found imported nicotine pouches were being sold in the departure zone without the necessary approvals, government documents show.
"Nicotine pouches also fall under the definition of a drug ... a valid registration certificate and import license are mandatory," an assistant drugs controller wrote in an April 2 letter to the airport's customs authority, attaching an "investigation report".
The government asked Mumbai Travel Retail, a joint venture led by Adani with Dubai's Flemingo, to discontinue sales of nicotine pouches and seek approvals, government letters show.
Adani did not respond to Reuters queries ahead of the story’s publication. Late on Wednesday, its spokesperson said in an email that the characterisation of "the matter as a 'breach of law' is premature and legally unsustainable", adding that Mumbai Travel Retail has “challenged the regulatory interpretation through judicial review.”
“International passengers arriving in India may lawfully carry nicotine pouches purchased overseas for personal consumption," the Adani statement said. "Yet the sale of identical products through an international duty-free channel has been treated differently. This apparent inconsistency forms part of the legal challenge."
Flemingo and the Indian health and customs authority did not respond to requests for comment.
Selling a drug without a license could draw a prison term of at least three years and a fine of at least 100,000 rupees ($1,000) or three times the value of the drugs confiscated, whichever is higher.
Reuters is first to report the details of the investigation into Adani sales and its court challenge in Mumbai.
Adani's firm has told authorities the shops in the international departure area conduct business "beyond the customs frontiers of India" and are outside the reach of domestic regulations, its non-public High Court filing shows.
CAN GUNS BE SOLD AT AIRPORT?
Asked about the Adani group's point, Murali Neelakantan, former general counsel at Indian drugmakers Cipla and Glenmark Pharmaceuticals, told Reuters: "If a murder occurs in the store, will Indian police have no powers to arrest? They will have ... Can (the store) sell guns or ammunition? No."
The Adani statement responded: "Firearms are prohibited from duty free retail world over because they pose an inherent threat to aviation safety. Drawing a parallel between firearms and regulated nicotine products has no bearing on the legal issues before the Court."
On June 24, judges in Mumbai's High Court said "no coercive action" should be taken on the existing stock of pouches at Mumbai's duty-free shops, scheduling the case for a July 14 hearing.
Adani runs eight airports in India and is targeting an $11 billion expansion that includes a bet on duty-free offerings. At Mumbai's international airport, it runs more than 30 duty-free shops.
In court, Adani said nicotine pouches "are not a drug" and are a "recent innovation" that was not anticipated by existing tobacco control laws, documents show.
Since August, Adani's firm imported Philip Morris' PM.N Zyn nicotine pouches in various flavours worth more than $29,000, and the White Fox brand from Swedish Smokeless Solutions worth $7,700, customs records showed. Those companies did not respond to Reuters queries.
Philip Morris says Zyn's U.S. sales doubled last year from 2023. The June Indian government study said both Zyn and White Fox were being sold by Indian vendors illegally.
Separately, Flemingo Dutyfree has told the High Court it operates shops at international seaports — including in Mumbai — and fears similar actions as it was "in the process of stocking" nicotine pouches, documents show.
Seeking licenses for nicotine pouches will compel suppliers to withdraw them from the market, making "the duty free industry in India unattractive to passengers," it said.
(Reporting by Aditya Kalra; Additional reporting by Arpan Chaturvedi; Editing by Thomas Derpinghaus and William Mallard)
((Email: [email protected]; X: @adityakalra;))
India considers nicotine pouches a new public health risk
Adani airport faces scrutiny of India drugs, customs officials
The group says drug, cosmetics law should not apply to such sales
Adani has mounted court challenge against scrutiny
By Aditya Kalra
NEW DELHI, July 7 (Reuters) - An Indian investigation found that Mumbai international airport's duty-free shops run by billionaire Gautam Adani's business group breached the law by selling nicotine pouches, which the government considers a public health hazard, according to documents from an investigation.
Adani denies wrongdoing and is asking judges to declare that a law covering drugs and cosmetics does not apply to duty-free shops and nicotine pouches, according to court papers reviewed by Reuters. Lawyers say the case could set a precedent on how India regulates sales at such outlets and a government win could block sales of one of the world's fastest-growing nicotine products in India's airports.
India banned e-cigarettes and approved certain nicotine replacements like patches and chewing gums following a registration process under the Drugs and Cosmetics Act. Nicotine pouches remain illegal and unapproved.
Tobacco kills 1.35 million people each year in India and a government study in June called nicotine pouches "a new and largely unregulated public health concern," with widespread illegal sales and consumption among people aged 18 to 40.
After receiving complaints from anti-nicotine group Mothers Against Vaping, India's drug department inspected duty-free shops at Mumbai's international airport in March and found imported nicotine pouches were being sold in the departure zone without the necessary approvals, government documents show.
"Nicotine pouches also fall under the definition of a drug ... a valid registration certificate and import license are mandatory," an assistant drugs controller wrote in an April 2 letter to the airport's customs authority, attaching an "investigation report."
Mumbai Travel Retail, a joint venture led by Adani with Dubai's Flemingo, was asked to discontinue sales of nicotine pouches and seek approvals, government letters show.
Adani declined to comment. Flemingo and the Indian health and customs authority did not respond to requests for comment.
Selling a drug without a license could draw a prison term of at least three years and a fine of at least 100,000 rupees ($1,049), or three times the value of the drugs confiscated, whichever is higher.
Reuters is first to report the details of the investigation into Adani sales and its court challenge in Mumbai.
CAN GUNS BE SOLD AT AIRPORT?
Adani's firm has told authorities the shops in the international departure area conduct business "beyond the customs frontiers of India" and are outside the regulatory reach of domestic regulations, its non-public High Court filing shows.
"If a murder occurs in the store, will Indian police have no powers to arrest? They will have ... Can they sell guns or ammunition? No," said Murali Neelakantan, who was previously general counsel at Indian drugmakers Cipla and Glenmark Pharmaceuticals.
On June 24, judges in Mumbai's High Court said "no coercive action" should be taken on the existing stock of pouches at Mumbai's duty-free shops, scheduling the case for a July 14 hearing.
POUCHES A "RECENT INNOVATION"
Adani runs eight airports in India and is targeting an $11 billion expansion that includes a bet on duty-free offerings. At Mumbai's international airport, it runs more than 30 duty-free shops.
In court, Adani said nicotine pouches "are not a drug" and are a "recent innovation" that was not anticipated by existing tobacco control laws, documents show.
Since August, Adani's firm imported Philip Morris' PM.N Zyn nicotine pouches in various flavours worth more than $29,000, and the White Fox brand from Swedish Smokeless Solutions worth $7,700, customs records showed. The companies did not respond to Reuters queries.
Philip Morris says Zyn's U.S. sales in 2025 doubled from 2023. The June Indian government study said both Zyn and White Fox were being sold by Indian vendors illegally.
Separately, Flemingo Dutyfree has told the High Court it operates shops at international seaports - including in Mumbai - and fears similar actions as it was "in the process of stocking" nicotine pouches, documents show.
Seeking licenses for nicotine pouches will compel suppliers to withdraw them from the market, making "the duty free industry in India unattractive to passengers," it said.
(Reporting by Aditya Kalra; Additional reporting by Arpan Chaturvedi; Editing by Thomas Derpinghaus)
((Email: [email protected]; X: @adityakalra;))
India considers nicotine pouches a new public health risk
Adani airport faces scrutiny of India drugs, customs officials
The group says drug, cosmetics law should not apply to such sales
Adani has mounted court challenge against scrutiny
By Aditya Kalra
NEW DELHI, July 7 (Reuters) - An Indian investigation found that Mumbai international airport's duty-free shops run by billionaire Gautam Adani's business group breached the law by selling nicotine pouches, which the government considers a public health hazard, according to documents from an investigation.
Adani denies wrongdoing and is asking judges to declare that a law covering drugs and cosmetics does not apply to duty-free shops and nicotine pouches, according to court papers reviewed by Reuters. Lawyers say the case could set a precedent on how India regulates sales at such outlets and a government win could block sales of one of the world's fastest-growing nicotine products in India's airports.
India banned e-cigarettes and approved certain nicotine replacements like patches and chewing gums following a registration process under the Drugs and Cosmetics Act. Nicotine pouches remain illegal and unapproved.
Tobacco kills 1.35 million people each year in India and a government study in June called nicotine pouches "a new and largely unregulated public health concern," with widespread illegal sales and consumption among people aged 18 to 40.
After receiving complaints from anti-nicotine group Mothers Against Vaping, India's drug department inspected duty-free shops at Mumbai's international airport in March and found imported nicotine pouches were being sold in the departure zone without the necessary approvals, government documents show.
"Nicotine pouches also fall under the definition of a drug ... a valid registration certificate and import license are mandatory," an assistant drugs controller wrote in an April 2 letter to the airport's customs authority, attaching an "investigation report."
Mumbai Travel Retail, a joint venture led by Adani with Dubai's Flemingo, was asked to discontinue sales of nicotine pouches and seek approvals, government letters show.
Adani declined to comment. Flemingo and the Indian health and customs authority did not respond to requests for comment.
Selling a drug without a license could draw a prison term of at least three years and a fine of at least 100,000 rupees ($1,049), or three times the value of the drugs confiscated, whichever is higher.
Reuters is first to report the details of the investigation into Adani sales and its court challenge in Mumbai.
CAN GUNS BE SOLD AT AIRPORT?
Adani's firm has told authorities the shops in the international departure area conduct business "beyond the customs frontiers of India" and are outside the regulatory reach of domestic regulations, its non-public High Court filing shows.
"If a murder occurs in the store, will Indian police have no powers to arrest? They will have ... Can they sell guns or ammunition? No," said Murali Neelakantan, who was previously general counsel at Indian drugmakers Cipla and Glenmark Pharmaceuticals.
On June 24, judges in Mumbai's High Court said "no coercive action" should be taken on the existing stock of pouches at Mumbai's duty-free shops, scheduling the case for a July 14 hearing.
POUCHES A "RECENT INNOVATION"
Adani runs eight airports in India and is targeting an $11 billion expansion that includes a bet on duty-free offerings. At Mumbai's international airport, it runs more than 30 duty-free shops.
In court, Adani said nicotine pouches "are not a drug" and are a "recent innovation" that was not anticipated by existing tobacco control laws, documents show.
Since August, Adani's firm imported Philip Morris' PM.N Zyn nicotine pouches in various flavours worth more than $29,000, and the White Fox brand from Swedish Smokeless Solutions worth $7,700, customs records showed. The companies did not respond to Reuters queries.
Philip Morris says Zyn's U.S. sales in 2025 doubled from 2023. The June Indian government study said both Zyn and White Fox were being sold by Indian vendors illegally.
Separately, Flemingo Dutyfree has told the High Court it operates shops at international seaports - including in Mumbai - and fears similar actions as it was "in the process of stocking" nicotine pouches, documents show.
Seeking licenses for nicotine pouches will compel suppliers to withdraw them from the market, making "the duty free industry in India unattractive to passengers," it said.
(Reporting by Aditya Kalra; Additional reporting by Arpan Chaturvedi; Editing by Thomas Derpinghaus)
((Email: [email protected]; X: @adityakalra;))
July 6 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - UNIT LAUNCHES OLANZAPINE FOR INJECTION, 10 MG/VIAL, SINGLE-DOSE VIAL
Source text: ID:nNSEby57T0
Further company coverage: GLEN.NS
(([email protected];))
July 6 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - UNIT LAUNCHES OLANZAPINE FOR INJECTION, 10 MG/VIAL, SINGLE-DOSE VIAL
Source text: ID:nNSEby57T0
Further company coverage: GLEN.NS
(([email protected];))
July 2 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - UNIT ADVANCES MULTI-COUNTRY PHASE 3 TRIAL FOR TRASTUZUMAB REZETECAN IN PLATINUM-RESISTANT OVARIAN CANCER
Source text: ID:nBSE55fTLy
Further company coverage: GLEN.NS
(([email protected];))
July 2 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - UNIT ADVANCES MULTI-COUNTRY PHASE 3 TRIAL FOR TRASTUZUMAB REZETECAN IN PLATINUM-RESISTANT OVARIAN CANCER
Source text: ID:nBSE55fTLy
Further company coverage: GLEN.NS
(([email protected];))
June 11 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - LAUNCHES WINLEVI (CLASCOTERONE) 10 MG/G CREAM IN KEY EUROPEAN MARKETS
Source text: ID:nBSE1cHzrV
Further company coverage: GLEN.NS
(([email protected];;))
June 11 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - LAUNCHES WINLEVI (CLASCOTERONE) 10 MG/G CREAM IN KEY EUROPEAN MARKETS
Source text: ID:nBSE1cHzrV
Further company coverage: GLEN.NS
(([email protected];;))
June 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC USA LAUNCHES LACOSAMIDE INJECTION USP
Source text: ID:nBSE7xtZqY
Further company coverage: GLEN.NS
(([email protected];))
June 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - GLENMARK PHARMACEUTICALS INC USA LAUNCHES LACOSAMIDE INJECTION USP
Source text: ID:nBSE7xtZqY
Further company coverage: GLEN.NS
(([email protected];))
May 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA Q4 CONSOL NET PROFIT 3.01 BILLION RUPEES
GLENMARK PHARMA Q4 CONSOL NET SALES 37.6 BILLION RUPEES
GLENMARK PHARMA - DECLARES DIVIDEND OF 2.5 RUPEES PER SHARE
Source text: [ID:]
Further company coverage: GLEN.NS
(([email protected];))
May 29 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA Q4 CONSOL NET PROFIT 3.01 BILLION RUPEES
GLENMARK PHARMA Q4 CONSOL NET SALES 37.6 BILLION RUPEES
GLENMARK PHARMA - DECLARES DIVIDEND OF 2.5 RUPEES PER SHARE
Source text: [ID:]
Further company coverage: GLEN.NS
(([email protected];))
May 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 MG/VIAL AND 1 G/VIAL
Source text: ID:nBSE93bDRP
Further company coverage: GLEN.NS
(([email protected];))
May 18 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - LAUNCHES VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP, 500 MG/VIAL AND 1 G/VIAL
Source text: ID:nBSE93bDRP
Further company coverage: GLEN.NS
(([email protected];))
April 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
RECEIVES U.S. FDA APPROVAL FOR PROGESTERONE VAGINAL INSERTS, 100 MG
Source text: ID:nNSE8j4qcP
Further company coverage: GLEN.NS
(([email protected];))
April 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
RECEIVES U.S. FDA APPROVAL FOR PROGESTERONE VAGINAL INSERTS, 100 MG
Source text: ID:nNSE8j4qcP
Further company coverage: GLEN.NS
(([email protected];))
April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - TO DIRECTLY COMMERCIALIZE AND DISTRIBUTE RYALTRIS IN U.S. EFFECTIVE APRIL 1, 2026
Source text: ID:nBSE33lGVw
Further company coverage: GLEN.NS
(([email protected];))
April 1 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - TO DIRECTLY COMMERCIALIZE AND DISTRIBUTE RYALTRIS IN U.S. EFFECTIVE APRIL 1, 2026
Source text: ID:nBSE33lGVw
Further company coverage: GLEN.NS
(([email protected];))
SHANGHAI, March 25 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's biggest drugmaker by market value, reported fourth-quarter profit below market expectations on Wednesday, as income from business development deals has failed to appear.
The specialist in oncology, neurology, immunology, respiratory, metabolic and cardiovascular drugs has expanded licensing deals and developed more innovative drugs amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.
In September, Hengrui agreed to grant a paid licence for its innovative cancer drug, trastuzumab rezetecan, to the Swiss arm of India's Glenmark Pharmaceuticals GLEN.NS, with an upfront payment of $18 million under the deal.
The deal was a part of a string of new licensing agreements earlier last year with overseas drugmakers such as Merck MRK.N and Britain's GSK GSK.L.
Hengrui's revenue from innovative drug sales increased 26.09% in 2025 but revenue from generic drug slipped, it said in its annual report.
The company recorded 1.96 billion yuan ($284.10 million) in net profit attributable to shareholders for the quarter ended December 31, its annual report showed, below HSBC Qianhai Securities analysts' estimate of 2.7 billion yuan.
Net profit for the entire 2025 rose 21.69% to 7.71 billion yuan.
($1 = 6.8989 Chinese yuan renminbi)
(Reporting by Andrew Silver, Editing by Louise Heavens)
SHANGHAI, March 25 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's biggest drugmaker by market value, reported fourth-quarter profit below market expectations on Wednesday, as income from business development deals has failed to appear.
The specialist in oncology, neurology, immunology, respiratory, metabolic and cardiovascular drugs has expanded licensing deals and developed more innovative drugs amid Beijing's centralised bulk buying programmes, which have squeezed generic drug revenues.
In September, Hengrui agreed to grant a paid licence for its innovative cancer drug, trastuzumab rezetecan, to the Swiss arm of India's Glenmark Pharmaceuticals GLEN.NS, with an upfront payment of $18 million under the deal.
The deal was a part of a string of new licensing agreements earlier last year with overseas drugmakers such as Merck MRK.N and Britain's GSK GSK.L.
Hengrui's revenue from innovative drug sales increased 26.09% in 2025 but revenue from generic drug slipped, it said in its annual report.
The company recorded 1.96 billion yuan ($284.10 million) in net profit attributable to shareholders for the quarter ended December 31, its annual report showed, below HSBC Qianhai Securities analysts' estimate of 2.7 billion yuan.
Net profit for the entire 2025 rose 21.69% to 7.71 billion yuan.
($1 = 6.8989 Chinese yuan renminbi)
(Reporting by Andrew Silver, Editing by Louise Heavens)
March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.
The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.
Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.
Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.
Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:
SUN PHARMACEUTICAL SUN.NS
India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.
DR REDDY'S LABORATORIES REDY.NS
The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.
ZYDUS LIFESCIENCES ZYDU.NS
The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.
TORRENT PHARMACEUTICALS TORP.NS
The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.
GLENMARK PHARMACEUTICALS GLEN.NS
Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).
ALKEM LABORATORIES ALKE.NS
The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.
ERIS LIFESCIENCES ERIS.NS
The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.
($1 = 93.9000 Indian rupees)
(Reporting by Rishika Sadam; Editing by Rashmi Aich)
(([email protected];))
March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.
The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.
Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.
Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.
Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:
SUN PHARMACEUTICAL SUN.NS
India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.
DR REDDY'S LABORATORIES REDY.NS
The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.
ZYDUS LIFESCIENCES ZYDU.NS
The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.
TORRENT PHARMACEUTICALS TORP.NS
The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.
GLENMARK PHARMACEUTICALS GLEN.NS
Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).
ALKEM LABORATORIES ALKE.NS
The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.
ERIS LIFESCIENCES ERIS.NS
The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.
($1 = 93.9000 Indian rupees)
(Reporting by Rishika Sadam; Editing by Rashmi Aich)
(([email protected];))
March 4 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK SPECIALTY SA RECEIVES U.S. FDA APPROVAL FOR FLUTICASONE PROPIONATE INHALATION AEROSOL USP, 44 MCG PER ACTUATION, WITH 180-DAY COMPETITIVE GENERIC THERAPY EXCLUSIVITY
GLENMARK PHARMA - TO DISTRIBUTE FLUTICASONE PROPIONATE INHALATION AEROSOL IN U.S. STARTING MARCH 2026
Source text: ID:nPn2YYB0ka
Further company coverage: GLEN.NS
(([email protected];))
March 4 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK SPECIALTY SA RECEIVES U.S. FDA APPROVAL FOR FLUTICASONE PROPIONATE INHALATION AEROSOL USP, 44 MCG PER ACTUATION, WITH 180-DAY COMPETITIVE GENERIC THERAPY EXCLUSIVITY
GLENMARK PHARMA - TO DISTRIBUTE FLUTICASONE PROPIONATE INHALATION AEROSOL IN U.S. STARTING MARCH 2026
Source text: ID:nPn2YYB0ka
Further company coverage: GLEN.NS
(([email protected];))
Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
TO LAUNCH SODIUM PHOSPHATES INJECTION IN USA
SODIUM PHOSPHATES INJECTION DISTRIBUTION TO BEGIN IN APRIL 2026
Source text: ID:nNSE1w4VMD
Further company coverage: GLEN.NS
(([email protected];;))
Feb 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
TO LAUNCH SODIUM PHOSPHATES INJECTION IN USA
SODIUM PHOSPHATES INJECTION DISTRIBUTION TO BEGIN IN APRIL 2026
Source text: ID:nNSE1w4VMD
Further company coverage: GLEN.NS
(([email protected];;))
Jan 30 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA Q3 CONSOL NET PROFIT 4.03 BILLION RUPEES
GLENMARK PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 39.01 BILLION RUPEES
Source text: [ID:]
Further company coverage: GLEN.NS
(([email protected];))
Jan 30 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA Q3 CONSOL NET PROFIT 4.03 BILLION RUPEES
GLENMARK PHARMA Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 39.01 BILLION RUPEES
Source text: [ID:]
Further company coverage: GLEN.NS
(([email protected];))
AcuCort AB has signed a commercial agreement with Glenmark Pharmaceuticals Limited for the marketing and distribution of its product, Zeqmelit®, in six European countries: Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. The agreement replaces a previous Letter of Intent and finalizes all commercial terms between the parties. Glenmark will be responsible for commercializing Zeqmelit® and submitting marketing authorization applications in these markets, with submissions expected in the second half of 2026. This agreement follows recent product launches and repeat orders in the Nordic region.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief on January 22, 2026, and is solely responsible for the information contained therein.
AcuCort AB has signed a commercial agreement with Glenmark Pharmaceuticals Limited for the marketing and distribution of its product, Zeqmelit®, in six European countries: Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. The agreement replaces a previous Letter of Intent and finalizes all commercial terms between the parties. Glenmark will be responsible for commercializing Zeqmelit® and submitting marketing authorization applications in these markets, with submissions expected in the second half of 2026. This agreement follows recent product launches and repeat orders in the Nordic region.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief on January 22, 2026, and is solely responsible for the information contained therein.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced it has entered into a license agreement with Glenmark Specialty S.A. regarding Trastuzumab Rezetecan. Under the terms of the agreement, Glenmark Specialty will pay royalties to Hengrui and the two parties will establish a joint product development and commercialization committee, with each appointing up to two representatives. The agreement will remain in effect until the expiration of the royalty term for Trastuzumab Rezetecan, unless terminated earlier or renewed by mutual consent. The contract is governed by the laws of Singapore. Hengrui stated it will continue to fulfill its information disclosure obligations and provide updates on the project's progress as appropriate.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced it has entered into a license agreement with Glenmark Specialty S.A. regarding Trastuzumab Rezetecan. Under the terms of the agreement, Glenmark Specialty will pay royalties to Hengrui and the two parties will establish a joint product development and commercialization committee, with each appointing up to two representatives. The agreement will remain in effect until the expiration of the royalty term for Trastuzumab Rezetecan, unless terminated earlier or renewed by mutual consent. The contract is governed by the laws of Singapore. Hengrui stated it will continue to fulfill its information disclosure obligations and provide updates on the project's progress as appropriate.
** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks
** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod
** Company says clinical trial applications are underway in Russia, Brazil, and Mexico
** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG
** Stock up 27.3% YTD
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Glenmark Pharma GLEN.NS rise 2.8% to 2,047.3 rupees, their highest in over 3 weeks
** Drugmaker starts phase 3 trial of cancer drug Envafolimab in India after drug regulator's nod
** Company says clinical trial applications are underway in Russia, Brazil, and Mexico
** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG
** Stock up 27.3% YTD
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Glenmark Pharmaceuticals GLEN.NS up 3.5% to 1985 rupees
** HSBC Global Investment Research retains "buy" rating and PT of 2,380 rupees ($27.20) on GLEN on the back of good visibility on growth drivers
** Easing R&D spend, start of supplies from Monroe plant, U.S. FDA approval for gFlovent, pick-up in the U.S. and India businesses led by new launches are key drivers for GLEN's growth - HSBC
** Stock set to rise most in a session since July 11
** Stock has been above its 100-day, 200-day simple moving avgs since June, indicating bullish sentiment
** Avg rating of nine analysts is "buy" and median PT is 2,380 rupees, ~19% higher than current price - data compiled by LSEG
** YTD, GLEN up ~24%
($1 = 87.5060 Indian rupees)
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
** Shares of Glenmark Pharmaceuticals GLEN.NS up 3.5% to 1985 rupees
** HSBC Global Investment Research retains "buy" rating and PT of 2,380 rupees ($27.20) on GLEN on the back of good visibility on growth drivers
** Easing R&D spend, start of supplies from Monroe plant, U.S. FDA approval for gFlovent, pick-up in the U.S. and India businesses led by new launches are key drivers for GLEN's growth - HSBC
** Stock set to rise most in a session since July 11
** Stock has been above its 100-day, 200-day simple moving avgs since June, indicating bullish sentiment
** Avg rating of nine analysts is "buy" and median PT is 2,380 rupees, ~19% higher than current price - data compiled by LSEG
** YTD, GLEN up ~24%
($1 = 87.5060 Indian rupees)
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected]; +91 8697274436;))
Sept 2 (Reuters) - Glenmark Pharmaceuticals GLEN.NS:
TO LAUNCH ERIBULIN MESYLATE INJECTION IN USA
TO BEGIN DISTRIBUTION IN SEPTEMBER 2025
Source text: ID:nBSE5B7S0j
Further company coverage: GLEN.NS
(([email protected];))
Sept 2 (Reuters) - Glenmark Pharmaceuticals GLEN.NS:
TO LAUNCH ERIBULIN MESYLATE INJECTION IN USA
TO BEGIN DISTRIBUTION IN SEPTEMBER 2025
Source text: ID:nBSE5B7S0j
Further company coverage: GLEN.NS
(([email protected];))
Aug 19 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMACEUTICALS INC TO LAUNCH MICAFUNGIN FOR INJECTION USP
Source text: ID:nnAZN4DSC95
Further company coverage: GLEN.NS
(([email protected];;))
Aug 19 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMACEUTICALS INC TO LAUNCH MICAFUNGIN FOR INJECTION USP
Source text: ID:nnAZN4DSC95
Further company coverage: GLEN.NS
(([email protected];;))
** Shares of Glenmark Pharma GLEN.NS fall 1.45% to 2,014.9 rupees
** Drugmaker's Q1 consol PBT fell 9% to 4.19 bln rupees ($47.96 million), net sales down by 5% at 30.59 bln rupees hit by pricing pressure in North America and Europe
** Sales in North America slipped 0.4%, while that in Europe dropped 4% for the quarter
** Europe and Emerging markets businesses to deliver a double-digit growth from Q2 onwards, chairman says
** 9 analysts covering GLEN have a "buy" rating on average, median PT is 2,365 rupees - data compiled by LSEG
** Stock up ~25% YTD
($1 = 87.3675 Indian rupees)
(Reporting by Urvi Dugar)
** Shares of Glenmark Pharma GLEN.NS fall 1.45% to 2,014.9 rupees
** Drugmaker's Q1 consol PBT fell 9% to 4.19 bln rupees ($47.96 million), net sales down by 5% at 30.59 bln rupees hit by pricing pressure in North America and Europe
** Sales in North America slipped 0.4%, while that in Europe dropped 4% for the quarter
** Europe and Emerging markets businesses to deliver a double-digit growth from Q2 onwards, chairman says
** 9 analysts covering GLEN have a "buy" rating on average, median PT is 2,365 rupees - data compiled by LSEG
** Stock up ~25% YTD
($1 = 87.3675 Indian rupees)
(Reporting by Urvi Dugar)
Aug 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
APPROVES TRANSFER OF CONSUMER CARE BUSINESS TO SUBSIDIARY
BUSINESS TRANSFER VALUED AT 2.40 BILLION RUPEES
Source text: ID:nBSE9HGC1t
Further company coverage: GLEN.NS
(([email protected];))
Aug 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
APPROVES TRANSFER OF CONSUMER CARE BUSINESS TO SUBSIDIARY
BUSINESS TRANSFER VALUED AT 2.40 BILLION RUPEES
Source text: ID:nBSE9HGC1t
Further company coverage: GLEN.NS
(([email protected];))
Adds analyst comment in paragraphs 6-7; updates shares
By Kashish Tandon
July 11 (Reuters) - Shares of India's Glenmark Pharmaceuticals GLEN.NS jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie ABBV.N for its early-stage blood cancer treatment.
The stock was the top percentage gainer on the Nifty Pharma index .NIPHARM, which traded 0.3% higher compared to a 0.8% loss in the benchmark Nifty 50 .NSEI.
AbbVie will get the exclusive rights to develop and commercialise ISB 2001 in North America, Europe, Japan and Greater China, according to the deal. Ichnos Glenmark Innovation (IGI) will receive an upfront payment of $700 million and could earn up to $1.22 billion in additional milestone payments.
"This is possibly the biggest deal by an Indian company in the biotechnology space," said Shrikant Akolkar, an analyst at brokerage Nuvama.
Nomura expects IGI to ramp up its research and development spending post the deal as "it is now well funded" and added that Glenmark could likely pursue an initial public offering for IGI in the near to medium term.
The deal validates the improved commercial prospects of innovative research and development, Motilal Oswal said. The brokerage raised its target price on the stock to 2,430 rupees from 1,690 rupees - the highest among nine analysts covering the stock, according to data compiled by LSEG.
Analysts, on average, rate the stock "buy", with the median price target at 1,665 rupees, well below current levels.
Glenmark is the best performer on the 20-member pharma index so far this year, gaining 30% versus a 4.8% decline in the sub-index.
(Additional reporting and writing by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)
(([email protected]; X: @MukherjeeHritam;))
Adds analyst comment in paragraphs 6-7; updates shares
By Kashish Tandon
July 11 (Reuters) - Shares of India's Glenmark Pharmaceuticals GLEN.NS jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie ABBV.N for its early-stage blood cancer treatment.
The stock was the top percentage gainer on the Nifty Pharma index .NIPHARM, which traded 0.3% higher compared to a 0.8% loss in the benchmark Nifty 50 .NSEI.
AbbVie will get the exclusive rights to develop and commercialise ISB 2001 in North America, Europe, Japan and Greater China, according to the deal. Ichnos Glenmark Innovation (IGI) will receive an upfront payment of $700 million and could earn up to $1.22 billion in additional milestone payments.
"This is possibly the biggest deal by an Indian company in the biotechnology space," said Shrikant Akolkar, an analyst at brokerage Nuvama.
Nomura expects IGI to ramp up its research and development spending post the deal as "it is now well funded" and added that Glenmark could likely pursue an initial public offering for IGI in the near to medium term.
The deal validates the improved commercial prospects of innovative research and development, Motilal Oswal said. The brokerage raised its target price on the stock to 2,430 rupees from 1,690 rupees - the highest among nine analysts covering the stock, according to data compiled by LSEG.
Analysts, on average, rate the stock "buy", with the median price target at 1,665 rupees, well below current levels.
Glenmark is the best performer on the 20-member pharma index so far this year, gaining 30% versus a 4.8% decline in the sub-index.
(Additional reporting and writing by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)
(([email protected]; X: @MukherjeeHritam;))
Corrects typo in company name to 'AbbVie' in headline
July 10 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie ABBV.N have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2001.
Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China.
Subject to regulatory approvals, IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, according to the agreement.
(Reporting by Chandini Monnappa and Hritam Mukherjee in Bengaluru; Editing by Shreya Biswas)
(([email protected]; +918061822697;))
Corrects typo in company name to 'AbbVie' in headline
July 10 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie ABBV.N have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2001.
Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, Europe, Japan and Greater China.
Subject to regulatory approvals, IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in additional milestone payments, according to the agreement.
(Reporting by Chandini Monnappa and Hritam Mukherjee in Bengaluru; Editing by Shreya Biswas)
(([email protected]; +918061822697;))
AcuCort AB has announced a significant investment from its principal shareholder, LSIF, which has decided to exercise series TO 2 warrants amounting to at least SEK 1 million. This decision comes ahead of the final exercise date of June 20, 2025, underlining LSIF's confidence in AcuCort's commercial prospects. The investment is driven by the recent signing of a letter of intent with Glenmark Pharmaceuticals for the distribution and marketing of Zeqmelit® in six European countries. This strategic move is poised to enhance AcuCort's presence in key markets with a combined population exceeding 160 million. The subscription price for the new shares is set at SEK 0.75 each, and the exercise of TO 2 will result in the issuance of approximately 1.3 million new shares, further solidifying LSIF's stake in the company.
AcuCort AB has announced a significant investment from its principal shareholder, LSIF, which has decided to exercise series TO 2 warrants amounting to at least SEK 1 million. This decision comes ahead of the final exercise date of June 20, 2025, underlining LSIF's confidence in AcuCort's commercial prospects. The investment is driven by the recent signing of a letter of intent with Glenmark Pharmaceuticals for the distribution and marketing of Zeqmelit® in six European countries. This strategic move is poised to enhance AcuCort's presence in key markets with a combined population exceeding 160 million. The subscription price for the new shares is set at SEK 0.75 each, and the exercise of TO 2 will result in the issuance of approximately 1.3 million new shares, further solidifying LSIF's stake in the company.
AcuCort AB has announced a significant milestone in its expansion strategy by signing a Letter of Intent (LOI) with Glenmark Pharmaceuticals. This agreement focuses on the distribution and marketing of AcuCort's product, Zeqmelit®, in six European countries, including Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. Glenmark Pharmaceuticals, known for its extensive operations across over 80 countries, will handle the commercialization efforts in these regions. The collaboration covers a population of over 160 million people, highlighting the substantial commercial potential for Zeqmelit® in these markets. Following successful launches in the Nordic region, AcuCort aims to leverage this partnership as a springboard for further expansion. The parties plan to finalize negotiations and formalize the commercial agreement by 2025.
AcuCort AB has announced a significant milestone in its expansion strategy by signing a Letter of Intent (LOI) with Glenmark Pharmaceuticals. This agreement focuses on the distribution and marketing of AcuCort's product, Zeqmelit®, in six European countries, including Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. Glenmark Pharmaceuticals, known for its extensive operations across over 80 countries, will handle the commercialization efforts in these regions. The collaboration covers a population of over 160 million people, highlighting the substantial commercial potential for Zeqmelit® in these markets. Following successful launches in the Nordic region, AcuCort aims to leverage this partnership as a springboard for further expansion. The parties plan to finalize negotiations and formalize the commercial agreement by 2025.
June 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
TO LAUNCH DCGI-APPROVED ZANUBRUTINIB IN INDIA
ZANUBRUTINIB TO BE MARKETED AS BRUKINSA IN INDIA
Source text: ID:nBSE95v3F3
Further company coverage: GLEN.NS
(([email protected];;))
June 9 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
TO LAUNCH DCGI-APPROVED ZANUBRUTINIB IN INDIA
ZANUBRUTINIB TO BE MARKETED AS BRUKINSA IN INDIA
Source text: ID:nBSE95v3F3
Further company coverage: GLEN.NS
(([email protected];;))
May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.
Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.
Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.
Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.
The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.
Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.
The U.S. imports nearly a third of Indian pharma products sold overseas.
India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
(([email protected]; 8800437922;))
May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.
Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.
Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.
Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.
The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.
Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.
The U.S. imports nearly a third of Indian pharma products sold overseas.
India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
(([email protected]; 8800437922;))
May 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMACEUTICALS LTD - IGI RECEIVES FDA FAST TRACK DESIGNATION FOR ISB 2001
Source text: ID:nBSE1SYXkx
Further company coverage: GLEN.NS
(([email protected];;))
May 5 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMACEUTICALS LTD - IGI RECEIVES FDA FAST TRACK DESIGNATION FOR ISB 2001
Source text: ID:nBSE1SYXkx
Further company coverage: GLEN.NS
(([email protected];;))
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Glenmark Pharma. do?
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The Company is primarily engaged in the business of development, manufacturing and marketing of pharmaceutical products.
Who are the competitors of Glenmark Pharma.?
Glenmark Pharma. major competitors are Alkem Laboratories, Abbott India, Ipca Laboratories, Ajanta Pharma, Glaxosmithkline Phar, Gland Pharma, Aurobindo Pharma. Market Cap of Glenmark Pharma. is ₹64,766 Crs. While the median market cap of its peers are ₹47,636 Crs.
Is Glenmark Pharma. financially stable compared to its competitors?
Glenmark Pharma. seems to be less financially stable compared to its competitors. Altman Z score of Glenmark Pharma. is 6.61 and is ranked 7 out of its 8 competitors.
Does Glenmark Pharma. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Glenmark Pharma. latest dividend payout ratio is 6.74% and 3yr average dividend payout ratio is 15.23%
How has Glenmark Pharma. allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable
How strong is Glenmark Pharma. balance sheet?
Balance sheet of Glenmark Pharma. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Glenmark Pharma. improving?
Yes, profit is increasing. The profit of Glenmark Pharma. is ₹1,362 Crs for TTM, ₹1,047 Crs for Mar 2025 and -₹1,501.67 Crs for Mar 2024.
Is the debt of Glenmark Pharma. increasing or decreasing?
Yes, The net debt of Glenmark Pharma. is increasing. Latest net debt of Glenmark Pharma. is -₹1,176.26 Crs as of Mar-26. This is greater than Mar-25 when it was -₹1,215.19 Crs.
Is Glenmark Pharma. stock expensive?
Glenmark Pharma. is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Glenmark Pharma. is 47.56, while 3 year average PE is 26.28. Also latest EV/EBITDA of Glenmark Pharma. is 13.91 while 3yr average is 15.51.
Has the share price of Glenmark Pharma. grown faster than its competition?
Glenmark Pharma. has given better returns compared to its competitors. Glenmark Pharma. has grown at ~27.22% over the last 5yrs while peers have grown at a median rate of 10.83%
Is the promoter bullish about Glenmark Pharma.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Glenmark Pharma. is 46.65% and last quarter promoter holding is 46.65%.
Are mutual funds buying/selling Glenmark Pharma.?
The mutual fund holding of Glenmark Pharma. is decreasing. The current mutual fund holding in Glenmark Pharma. is 16.8% while previous quarter holding is 17.86%.